JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness
Engineering batch for JAN101 complete and expectations are for GMP batch production to begin within 30 days Las Vegas, NV – August 26, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has successfully completed its initial engineering batch […]
JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular Complications
-Introduction to JanOne scientific team -Strategy for upcoming planned Phase 2b trial of JAN101 -Business development updates, including planned COVID-19 treatment study and focus on commercialization and production capabilities Las Vegas, NV – August 21, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe […]
